FDA approves Eli Lilly Alzheimer’s drug, expanding treatment options in the U.S.

- FDA approved Eli Lilly's Alzheimer's drug donanemab, sold under the brand name Kisunla - Donanemab and a similar drug Leqembi from Biogen and Eisai are milestones in Alzheimer's treatment - Both drugs are monoclonal antibodies targeting toxic plaques in the brain to slow disease progression - Eli Lilly's drug slowed Alzheimer's progression by 35% over 18 months - Drug administered through monthly infusions, expected costs are $12,522 for a 6-month course - Drug is not a cure and comes with significant safety risks, including severe side effects - This is the third Alzheimer's drug to reach the market after Leqembi and an ill-fated therapy from Biogen and Eisai - FDA received criticism for expedited approval of Aduhelm in 2021 despite negative recommendation from an advisory panel

🚨 Reddit sentiment: mixed/negative - Comments are mixed but lean towards skepticism regarding the drug's effectiveness and high costs, leading to a generally negative outlook despite some positive remarks. Summarized comments: - That treatment will probably cost your firstborn child in the US so bullish af - Big pharma is stepping up as older generations control wealth - Concerns about the drug's effectiveness; some believe it barely works - Questions about if the news is priced in - Stock is down, leading to skepticism about the drug's value - Biden and Sanders' comments on expensive drugs impacting price - Some view the news as bullish - Doubts about the drug's effectiveness and concerns over selling false hope - High costs and side effects highlighted, skeptical views on true benefits - Bullish on fat Americans who can’t remember anything Stock tickers discussed: $LLY